Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 7/20 | 0.34 |
| ▸ | CA2 | P00918 | 7/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261562 | 0.92 | CA1 (0.37) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL4586536 | 0.81 | CA1 (0.37) | CA1CA2CA12CA9NOS3 | |
| SCHEMBL25515999 | 0.81 | NOS3 (0.40) | CA1CA2CA12CA9NOS3 | |
| SCHEMBL13850903 | 0.79 | ALDH1A1 (0.39) | LMNACA1CA2CA12CA9 | |
| SCHEMBL6905527 | 0.79 | P2RY10 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL19153577 | 0.79 | PRKCA (0.32) | — | |
| SCHEMBL19152428 | 0.79 | CA1 (0.42) | CA1CA2CA12CA9NOS3 | |
| SCHEMBL18119724 | 0.77 | NOS3 (0.41) | CA1CA2CA12CA9NOS3 | |
| SCHEMBL25515864 | 0.77 | CA1 (0.34) | CA1CA2CA12CA9NOS3 | |
| SCHEMBL18121926 | 0.77 | NOS2 (0.51) | KMT2ACA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137669-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | REGENTS OF THE UNIVERSITY OF NEBRASKA, BOARD OF | 2009-05-28 | — | — | US | claimed |
| US-20190247354-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2019-08-15 | — | — | US | disclosed |
| US-20180153844-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2018-06-07 | — | — | US | disclosed |
| US-9833427-B2 | Creatine ester anti-inflammatory compounds and formulations | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833427-B2 | Creatine ester anti-inflammatory compounds and formulations | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170202241-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2017-07-20 | — | — | US | disclosed |
| US-20170202241-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2017-07-20 | — | — | US | disclosed |
| US-20110224174-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2011-09-15 | — | — | US | disclosed |
| US-20110224174-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2011-09-15 | — | — | US | disclosed |
| US-20110172306-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | VENNERSTROM JONATHAN L | 2011-07-14 | — | — | US | disclosed |
| US-20110172306-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | VENNERSTROM JONATHAN L | 2011-07-14 | — | — | US | disclosed |
| US-20090137669-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | REGENTS OF THE UNIVERSITY OF NEBRASKA, BOARD OF | 2009-05-28 | — | — | US | disclosed |
| US-20090137669-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | REGENTS OF THE UNIVERSITY OF NEBRASKA, BOARD OF | 2009-05-28 | — | — | US | disclosed |
| US-20070203076-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | VENNERSTROM JONATHAN L | 2007-08-30 | — | — | US | disclosed |
| US-20070203076-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | VENNERSTROM JONATHAN L | 2007-08-30 | — | — | US | disclosed |
| EP-1324760-B1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | UNIV NEBRASKA (US) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153844-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, CRAT | KDM4E 809/4885DUSP3 4181/4885MEN1 4868/4885 |
| US-20190247354-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, CRAT | KDM4E 809/4885DUSP3 4181/4885MEN1 4868/4885 |
| US-20170202241-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, PYGM | KDM4E 835/4885DUSP3 4721/4885MEN1 4148/4885 |
| US-20110172306-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, PYGM | KDM4E 835/4885DUSP3 4721/4885MEN1 4148/4885 |
| US-20110224174-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, CRAT | KDM4E 809/4885DUSP3 4181/4885MEN1 4868/4885 |
| US-20070203076-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, PYGM | KDM4E 835/4885DUSP3 4721/4885MEN1 4148/4885 |
| US-20090137669-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, CRAT | KDM4E 809/4885DUSP3 4181/4885MEN1 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.